End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.336 EUR | +24.44% | -91.94% | -88.41% |
Apr. 26 | Acticor Biotech: rebound from the previous day's tumble | CF |
Apr. 25 | Acticor Biotech: Phase 2/3 study fails | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-88.41% | 4.71M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- ALACT Stock
- News Acticor Biotech SAS
- Acticor Biotech’s Phase 2/3 Trial for Stroke Drug Combo on Track for 2024 Results